Clinical trials
Recruiting Hematologic Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
274 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 7 |
| 2018 | 5 |
| 2019 | 9 |
| 2020 | 10 |
| 2021 | 19 |
| 2022 | 31 |
| 2023 | 37 |
| 2024 | 41 |
| 2025 | 50 |
| 2026 | 43 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 274 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 19 |
| National Cancer Institute (NCI) | 8 |
| Cancer Research UK | 7 |
| St. Jude Children's Research Hospital | 6 |
| Massachusetts General Hospital | 5 |
| Tata Memorial Centre | 5 |
| Dana-Farber Cancer Institute | 4 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| University of Alabama at Birmingham | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Neoplasms | 274 |
| Neoplasms | 37 |
| Leukemia, Myeloid, Acute | 35 |
| Leukemia | 32 |
| Multiple Myeloma | 27 |
| Lymphoma | 25 |
| Lymphoma, Non-Hodgkin | 19 |
| Myelodysplastic Syndromes | 19 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 19 |
| Graft vs Host Disease | 15 |
Trials
Showing 1 to 25 of 274. Each trial links to its page on Pharma Observatory.
174 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.